<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7094151/table_2" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 2</label>
  <p>Efficacy and Adverse Effects of Antiviral and Anti-Inflammatory Agents</p>
 </caption>
 <thead>
  <tr>
   <th rowspan="1" colspan="1" id="0-0-.">Treatment/Management</th>
   <th rowspan="1" colspan="1" id="0-1-.">Efficacy</th>
   <th rowspan="1" colspan="1" id="0-2-.">Adverse Effects</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td rowspan="1" colspan="1">PVI irrigation</td>
   <td rowspan="1" colspan="1">Off-label use for EKC; reduces risk of disease transmission</td>
   <td rowspan="1" colspan="1">Dry eye symptoms, corneal epithelial damage/toxicity with repeated use. 
    <a rid="CIT0104" ref-type="bibr">104</a>
   </td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Cidofovir</td>
   <td rowspan="1" colspan="1">Antiviral activity against HAdV5 exhibited in animal models. 
    <a rid="CIT0105" ref-type="bibr">105</a>
    <br/>Cidofovir 1% lowered the frequency of severe corneal opacities in patients with adenoviral keratoconjunctivitis. 
    <a rid="CIT0064" ref-type="bibr">64</a>, 
    <a rid="CIT0106" ref-type="bibr">106</a>
   </td>
   <td rowspan="1" colspan="1">Narrow therapeutic index when used topically; high doses for greater than one week associated with rare cases of lacrimal canalicular 
    <br/>blockade in rabbit models. 
    <a rid="CIT0107" ref-type="bibr">107</a>
   </td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Ganciclovir</td>
   <td rowspan="1" colspan="1">3% ganciclovir reduced HAdV 5 replication and pathogenesis in animal models. 
    <a rid="CIT0108" ref-type="bibr">108</a> Ganciclovir is efficacious against HAdV types that cause EKC. 
    <a rid="CIT0046" ref-type="bibr">46</a> Ganciclovir ophthalmic gel treatment prevents complications in adenoviral ocular infection. 
    <a rid="CIT0109" ref-type="bibr">109</a>
   </td>
   <td rowspan="1" colspan="1">Transient blur following instillation, eye irritation, punctate keratitis, conjunctival hyperemia. 
    <a rid="CIT0108" ref-type="bibr">108</a>
   </td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Brincidofovir</td>
   <td rowspan="1" colspan="1">Brincidofovir has antiviral activity against adenoviruses. 
    <a rid="CIT0055" ref-type="bibr">55</a>, 
    <a rid="CIT0105" ref-type="bibr">105</a>, 
    <a rid="CIT0110" ref-type="bibr">110</a>– 
    <a rid="CIT0113" ref-type="bibr">113</a>  
   </td>
   <td rowspan="1" colspan="1">Mild gastrointestinal tract upset, asymptomatic and elevated levels of serum transaminases 
    <a rid="CIT0114" ref-type="bibr">114</a> diarrhea, acute graft versus host disease, abdominal pain, nausea/vomiting, decreased appetite, peripheral edema, hyperglycemia, hypokalemia, rash, fatigue, fever. 
    <a rid="CIT0115" ref-type="bibr">115</a>
   </td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Topical corticosteroids</td>
   <td rowspan="1" colspan="1">Relief of EKC symptoms and Persistent adenoviral SEIs. 
    <a rid="CIT0002" ref-type="bibr">2</a>, 
    <a rid="CIT0063" ref-type="bibr">63</a>  
   </td>
   <td rowspan="1" colspan="1">Glaucoma and cataracts. 
    <a rid="CIT0116" ref-type="bibr">116</a>
   </td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Topical cyclosporine</td>
   <td rowspan="1" colspan="1">Effective against persistent adenoviral SEIs. 
    <a rid="CIT0066" ref-type="bibr">66</a>, 
    <a rid="CIT0069" ref-type="bibr">69</a>, 
    <a rid="CIT0117" ref-type="bibr">117</a>– 
    <a rid="CIT0119" ref-type="bibr">119</a>
   </td>
   <td rowspan="1" colspan="1">Transient or long-lasting burning sensation; 
    <a rid="CIT0120" ref-type="bibr">120</a> ocular pain/irritation, redness; eyelid swelling in Steven Johnsons patients. 
    <a rid="CIT0121" ref-type="bibr">121</a>
   </td>
  </tr>
  <tr>
   <td rowspan="1" colspan="1">Topical tacrolimus</td>
   <td rowspan="1" colspan="1">Superior to dexamethasone in reducing symptomology and SEIs 
    <a rid="CIT0070" ref-type="bibr">70</a> as well as a safe and effective treatment of adenoviral SEIs. 
    <a rid="CIT0087" ref-type="bibr">87</a>, 
    <a rid="CIT0122" ref-type="bibr">122</a>, 
    <a rid="CIT0123" ref-type="bibr">123</a>
   </td>
   <td rowspan="1" colspan="1">Transient burning sensation. 
    <a rid="CIT0124" ref-type="bibr">124</a>
   </td>
  </tr>
 </tbody>
</table>
